Therefore, our results uncover a novel mechanism for upregulation of ANGPT2 in cancer and indicate an oncogenic role for MYBL1 in HCC angiogenesis and sorafenib resistance. The gene discussed is ANGPT2; the disease is hepatocellular carcinoma.